Blood gene test links to obstructive lung disease after TB

Post-tuberculosis lung disease (PTLD) is a common and disabling consequence of pulmonary TB, affecting roughly half of people treated for the infection. Seeking a practical way to identify who will go on to have lingering lung damage, a team led by corresponding author Renee Newby followed a large group of newly diagnosed, treatment naïve adults with pulmonary TB. The researchers enrolled 301 participants into what they call cohort A and collected whole blood samples at the start of treatment (0 months) and after treatment (6 months). From those samples they isolated RNA and measured a compact immune response signature called the modified MTB Host Response (mHR) signature, which is based on expression of three genes: DUSP3, GBP5, and TMBIM6. The team also recruited household contacts (cohort B) to provide a comparison group without active PTB. Lung function was assessed using spirometry at 6 months (216 participants) and 12 months (210 participants) after treatment began, allowing the investigators to compare early blood signals with later lung outcomes and test whether a minimum gene signature could work as a clinically useful biomarker for PTLD.

The study used prospective enrollment and paired blood and lung function measures to test associations between the mHR score and clinical features. Whole-blood RNA measurements of the mHR signature distinguished people with TB from household contacts (p=4.15e-66) and tracked with treatment response (p=1.07e-53). The mHR score was also linked to clinical markers of disease severity, including CD4 count (p=0.003), bacillary load (p=3.02e-05), the presence of lung cavities (p=1.59e-04), and the number of lung quadrants involved on imaging (p=3.87e-06). The mHR score was not associated with Mtb aerosolization. At 12 months, half of participants (105, 50%) met criteria for PTLD: 61 had restrictive patterns, 26 had obstructive patterns, and 18 had mixed obstruction and restriction. Importantly, a higher baseline mHR score was associated specifically with obstructive PTLD at both 6 months (p=0.003) and 12 months (p=0.012) in both bivariate and multivariate analyses, while the mHR score was not associated with restrictive lung disease.

Taken together, these findings suggest that a very small blood gene set — the DUSP3, GBP5, TMBIM6-based mHR signature — measured before or at the start of treatment may help identify people at risk of developing obstructive forms of PTLD. Because the signature was linked to multiple measures of disease severity and to later obstructive impairment on spirometry, it has potential as a biomarker to guide closer follow-up, targeted interventions, or prognosis for patients treated for pulmonary TB. The authors conclude that baseline mHR was associated with obstructive PTLD at both 6 and 12 months and may have applications in targeting treatment and prognostication. Further work would be needed to validate the test in other groups and to determine how best to use it in clinical care, but the study points to a concise molecular signal that could complement imaging and lung function tests when planning post-TB care.